AzTrials
AzTrials

Colon Rectal CancerCCR-VINCatNCT04496635

Surveillance and Implementation of a Bundle of Care to Reduce Surgical Site Infection in Colorectal Surgery (CCR-VINCat)

A study testing Implementation of a bundle of care in people with Colon Rectal Cancer and Surgical Site Infection, run by Hospital de Granollers at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The Nosocomial Infection Surveillance Program in Catalonia (VINCat) monitors surgical site infection (SSI) in elective colorectal surgery since 2007 in 55 public and private acute care hospitals. These hospitals perform active and prospective standardized surveillance of elective colorectal resections. Read more about this study

Who is it for?
Any age
Conditions the study is for
Colon Rectal Cancer, Surgical Site Infection
What is being tested?
Implementation of a bundle of care
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60,000 participants
Where
1 siteSpain
Study dates
1 Jan 2007to 30 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Colon or rectal elective surgery.

Who cannot join

  • Peritonitis at the time of intervention ("dirty" surgery) Patients who underwent multiple procedures during the same surgery, for example resection of liver metastases Centers that performed less tan 10 surgical procedures annually Centers that have not been able to ensure prospective surveillance during hospitalization or effective monitoring of cases within 30 days of the intervention

Trial locations and contacts

1 site in 1 country.

Gemma Molist, MD, PHD contact

+348425000

gmolist@fphag.org

Josep M Badia, MD, PhD contact

+34670702099

jmbadiaperez@gmail.com

Spain1 site, 1 recruiting
  • Hospital General de Granollers

    Granollers, Barcelona, 08402

    Josep M Badia, 670702099, jmbadiaperez@gmail.com

    Recruiting

Other trials in Spain

About this study

Official title: Evaluation of the Application and Efficacy of Prevention Measures for Surgical Site Infection in Elective Colorectal Surgery.

The Nosocomial Infection Surveillance Program in Catalonia (VINCat) monitors surgical site infection (SSI) in elective colorectal surgery since 2007 in 55 public and private acute care hospitals. These hospitals perform active and prospective standardized surveillance of elective colorectal resections. Post-discharge surveillance is mandatory at least up to 30 days after surgery. Hospitals are classified according to their size into three groups: >500 hospital beds; 200-500 beds; <200 beds.

Aim. To examine the effect on SSI rate of a specific preventative bundle in elective colorectal surgery.

Read more

Methods. Pragmatic study using VINCat prospective colorectal database from 2007 to 2018. In 2016, a bundle of six preventative measures was recommended to the VINCat hospitals.

To compare the results of SSI before (baseline phase, BP) and after the bundle implementation (implementation phase, IP) a logistic regression model has been established. The results will be shown as Odds Ratio (OR) and the corresponding confidence intervalsCI95. The significance level will be fixed at 5% (P < 0.05).

Read the detailed description

Surveillance. The VINCat Program was developed in the 2007 as the Nosocomial Infection Surveillance system in Catalonia, covering a population of seven and a half million people. The system is similar to other international reference programs, such as the National Healthcare Safety Network (NHSN), and its described in detail on the VINCat website. Hospitals carry out active and prospective standardized surveillance, and are classified according to their number of beds into three groups: group 1 (500 beds); group 2 (200-500 beds); group 3 (200 beds). The staff performing surveillance had received training in the VINCat surveillance methodology to ensure the collection of homogeneous, accurate data.

Surveillance is continued at least for 30 days after the operation. All public and private participating hospitals report data voluntarily and receive feedback once a year.

Monitoring of colorectal surgery is performed prospectively and continued until a minimum of 100 interventions per year is reached in each hospital, although some centres include all their yearly cases. Hospitals with less than 10 interventions per year are excluded. Participating hospitals record the data on an Internet-based database.

Follow-up and post-discharge surveillance. Patients are followed up by trained infection control staff. Active mandatory post-discharge surveillance is performed at least to day 30 post surgery by a multimodal approach including electronic review of clinical records (primary and secondary care), checking readmissions, checking emergency visits, and reviewing microbiological and radiological data.

Development of the colorectal surgical site infection program. In 2015, a multidisciplinary team of nurses and medical specialists from the VINCat Program, and surgeons belonging to the Catalan Society of Surgery was set up to formulate a specific bundle of SSI preventative measures for colorectal surgery. The literature for optimal care during the preoperative, intraoperative and postoperative phases was reviewed, including evidence on oral antibiotic prophylaxis and mechanical bowel preparation. Practices were chosen either by their high levels of scientific evidence or by being considered, by consensus, reasonable, associated with minimal risk, and potentially beneficial.

The working group developed a 6 measures bundle to be voluntary implemented by the participating hospitals. The measures of the bundle are: intravenous and oral antibiotic prophylaxis, mechanical bowel preparation (MBP), laparoscopic surgery, maintenance of normothermia, and the use of a wound retractor.

The intervention began on 1 January 2016, with diffusion of the bundle measures via e-mail, and a workshop addressed to all to the surgical and ICT teams.

Definitions. SSI is defined according to the Centers for Disease Control (CDC) and is stratified into categories of surgical procedures (-1 to 3) according to the risk of surgical infection defined by the NHSN.

Design of the pragmatic trial. Implementation of the bundle precluded randomization. The study compared two phases: baseline (BP), from 2008 to 2015, and implementation (IP), from 2016 to 2018.

Fifty-five of the 66 hospitals participating in the VINCat Program were included in the analysis. Prospective surveillance was performed by the infection control team (ICT) of each hospital to ensure appropriate data collection. The surveillance period lasted from January 2007 to December 2018. During the first 4 years of the program, the results of colon and rectal surgery were aggregated. From 2011, data is separated for each type of surgery.

As all eligible patients were included in the pragmatic design, informed consent was not obtained.

The study was conducted as a performance improvement project and approved by the Ethics in Research Committee.

Statistical analysis Data will be summarized as frequencies and proportions for categorical variables or as medians and interquartile range (IQR) for continuous variables. Infection rates will be expressed as cumulative incidence, that is, the crude percentage of operations resulting in SSI/ number of surgery procedures. Data will be also stratified by year, risk index category, hospital group and SSI type.

To analyse the relationship between two qualitative variables, contingency tables will be used, and the chi-square test or the likelihood ratio test will be performed. The analysis will be completed with grouped bar graphs. To analyse differences in the proportion of infection over the years, the logistic regression model will be performed. The results will be presented in terms of OR or estimated infection rates, with the corresponding 95% confidence intervals. The significance level will be set at 5% in all tests. The results will be analysed using software: Statistical Analysis Systems (SAS) v9.4, SAS Institute Inc., Cary, USA.

Being tested
Implementation of a bundle of care
Keywords
Surveillance, Preventative measures, Bundle of care, Colorectal surgery, Surgical site infection, Prevention
Medical subject headings
Colonic Neoplasms, Surgical Wound Infection

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Implementation of a bundle of careOther

Study groups in NCT04496635
Study groupRoleWhat they receive
Baseline phaseNo interventionPatients included in the VINCat program, and operated on colorectal surgery between 2007 and 2015 in Catalonia
Implementation phaseExperimentalPatients included in the VINCat program, and operated on colorectal surgery between 2016 and 2018 in Catalonia
Receives: Other: Implementation of a bundle of care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Surgical site infection rate

    Overall surgical infection rate

    Measured: 30 days

Secondary outcomes (3)
  1. Organ/space surgical infection rate

    Specific organ/space surgical infection rate

    Measured: 30 days

  2. Hospital type-Surgical infection rate

    Comparison of rates among the three hospitals groups, according to their size

    Measured: 30 days

  3. Analysis (logistic regression model) of the efficacy of each preventive measure

    Univariate and multivariate logistic regression to analise the efficacy of each individual measure belonging to the bundle of care.

    Measured: 30 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Aug 2020
  2. Study start1 Jan 2007
  3. Primary completion30 Nov 2025 (estimated)
  4. Study completion30 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Sequential
Model description
The study compare two phases: baseline (BP), from 2008 to 2015, and implementation (IP), from 2016 to 2018.
Masking
None (open label)
Enrolment
60,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04496635
Sponsor's protocol ID
CCR-VINCat 1
Acronym
CCR-VINCat
Status last verified
Aug 2023
First submitted
14 Jul 2020
Last updated
22 Aug 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Data will be shared when requested

Questions about this trial

What is this clinical trial studying?

A study testing Implementation of a bundle of care in people with Colon Rectal Cancer and Surgical Site Infection, run by Hospital de Granollers at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Gemma Molist, MD, PHD (+348425000, gmolist@fphag.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Surgical site infection rate (time frame: 30 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Aug 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in